Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Metagenomi (MGX) EBIT Margin (2023 - 2025)

Metagenomi (MGX) has disclosed EBIT Margin for 3 consecutive years, with 623.04% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 40853.0% to 623.04% in Q4 2025 year-over-year; TTM through Dec 2025 was 380.85%, a 21085.0% decrease, with the full-year FY2025 number at 380.85%, down 21085.0% from a year prior.
  • EBIT Margin was 623.04% for Q4 2025 at Metagenomi, down from 263.76% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 84.28% in Q2 2024 to a low of 674.1% in Q1 2025.
  • A 3-year average of 272.54% and a median of 210.86% in 2023 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: skyrocketed 7416bps in 2024, then plummeted -41393bps in 2025.
  • Metagenomi's EBIT Margin stood at 162.88% in 2023, then plummeted by -32bps to 214.51% in 2024, then tumbled by -190bps to 623.04% in 2025.
  • Per Business Quant, the three most recent readings for MGX's EBIT Margin are 623.04% (Q4 2025), 263.76% (Q3 2025), and 246.53% (Q2 2025).